Atormac
Neurology India
Open access journal indexed with Index Medicus
  Users online: 2006  
 Home | Login 
  About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe Etcetera Contact  
  Navigate Here 
 Search
 
  
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
  »  Article in PDF (1,581 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

 
  In this Article
 »  Abstract
 » Mechanisms
 »  Clinical Manifes...
 » Medical Management
 »  Oncologic Treatm...
 » Surgical Management
 » Summary
 »  References
 »  Article Figures
 »  Article Tables

 Article Access Statistics
    Viewed1853    
    Printed67    
    Emailed0    
    PDF Downloaded69    
    Comments [Add]    

Recommend this journal

 


 
Table of Contents    
REVIEW ARTICLE
Year : 2017  |  Volume : 65  |  Issue : 7  |  Page : 60-70

Management of brain tumor-related epilepsy


1 Department of Neurosurgery, Wayne State University School of Medicine, Detroit, Michigan, USA
2 Department of Neurology, Wayne State University School of Medicine; Comprehensive Epilepsy Center, Detroit Medical Center and Wayne State University, Detroit, Michigan, USA
3 Department of Neurosurgery; Oncology, Wayne State University School of Medicine; Comprehensive Epilepsy Center, Detroit Medical Center and Wayne State University; Multidisciplinary Neuro-Oncology Program, Karmanos Cancer Institute, Detroit, Michigan, USA

Date of Web Publication8-Mar-2017

Correspondence Address:
Sandeep Mittal
Department of Neurosurgery, Wayne State University, 4160 John R Street, Suite 930, Detroit, Michigan - 48201
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/neuroindia.NI_1076_16

Rights and Permissions

 » Abstract 

Seizures are common in both primary and metastatic brain tumors, although the rate of seizures differ significantly between the different types of neoplasms. Patients with brain tumor-associated seizures need treatment with antiepileptic drugs (AEDs) to prevent recurrence, whereas strong clinical data exists to discourage routine prophylaxis in patients who have not had seizures. The newer AEDs, such as levetiracetam, lamotrigine, lacosamide, topiramate, or pregabalin, are preferable for various reasons, primarily related to the side-effect profile and limited interactions with other drugs. If seizures persist despite initiation of an appropriate monotherapy (in up to 30–40% of cases), additional anticonvulsants may be necessary. Early surgical intervention improves seizure outcomes in individuals with medically refractory epilepsy, especially in patients with a single lesion that is epileptogenic. Data for this review article were compiled by searching for scholarly articles using the following keywords: brain tumor, epilepsy, seizure, tumor-related epilepsy, central nervous system, epidemiology, review, clinical trial, and surgery. Articles were screened for relevance by title and abstract, and selected for review and inclusion based on significant contribution to the topics discussed.


Keywords: Epilepsy, seizure, tumor
Key Messages: Seizures are common but not universal in patients with a brain tumor. Prophylactic antiepileptic therapy is not recommended for patients with a brain tumor in the absence of seizures. Antiepileptic medications control seizures in the majority of patients with tumor-related epilepsy; however, a significant proportion will continue to suffer from seizures despite such treatment. The newer antiepileptic drugs, such as levetiracetam, lamotrigine, lacosamide, topiramate, or pregabalin, are as effective, but with fewer side effects and drug–drug interactions compared to the older generation anticonvulsants such as phenytoin, carbamazepine, and phenobarbitone. Surgical therapy is indicated when medications fail to control seizures, and success is predicted by the extent of resection, a shorter duration of seizures prior to surgery, and focal localization of seizures.


How to cite this article:
Klinger NV, Shah AK, Mittal S. Management of brain tumor-related epilepsy. Neurol India 2017;65, Suppl S1:60-70

How to cite this URL:
Klinger NV, Shah AK, Mittal S. Management of brain tumor-related epilepsy. Neurol India [serial online] 2017 [cited 2017 Nov 22];65, Suppl S1:60-70. Available from: http://www.neurologyindia.com/text.asp?2017/65/7/60/201664


Seizures are a relatively common presentation in both primary and metastatic brain tumors [Table 1].[1] Approximately 30–50% of patients with brain tumors experience a seizure at presentation. An additional 10–30% will develop seizures at some point during the course of their disease.[2],[3],[4],[5] It is important to note that the incidence of brain tumors as a cause of epilepsy is actually quite low, accounting for only approximately 4% of all patients with epilepsy.[4],[6]

Difficulty in managing epilepsy in patients with brain tumors stems from an overall resistance to medical therapy, frequent interactions between antiepileptic drugs (AEDs) and chemotherapeutic agents, and potential adverse effects of both medical and surgical treatment. Moreover, seizures significantly impact the quality of life, and continued seizures are associated with a poorer outcome. This review will focus on discussing the literature that investigates tumor-related epilepsy in the context of understanding practice guidelines for AED use and management of refractory cases.
Table 1: Seizure frequency by tumor type

Click here to view



 » Mechanisms Top


The pathogenesis of tumor-related epilepsy is not precisely known, though it certainly has a multifactorial pathogenesis [Figure 1].[7] The emergence of seizures may be caused by tumor histology and location, changes in neurotransmission, disruption of the blood–brain barrier, changes in gap junctions, molecular alterations, and alterations of the peritumoral environment, among other factors.
Figure 1: Schematic diagram of known mechanisms underlying the pathogenesis of tumor-related epilepsy. Adapted from You et al.[7]

Click here to view


Tumor histology and location

The incidence of epilepsy varies among patients with different types of primary brain tumors [Table 1].[4],[5],[9],[19],[129],[130],[131],[132] For example, patients with gliomas are more likely to experience seizures with a low-grade pathology compared with a high-grade one.[8],[9] A review of 1028 patients with primary brain tumors showed a difference of 49%, 69%, and 85% seizure prevalence in patients with World Health Organization (WHO) grade IV [glioblastoma multiforme (GBM)], WHO grade III (anaplastic glioma), and low-grade glioma, respectively.[9] Dysembryoplastic neuroepithelial tumors (DNETs) and gangliogliomas are developmental brain tumors that have a very high seizure incidence (>80%).[4],[10] The rate of tumor-related epilepsy differs on the basis of tumor location with the cortical location of the tumor commonly associated with the development of epileptic seizures. In contrast, infratentorial and sellar tumors rarely present with seizures. Further, occipital lobe lesions are less frequently associated with seizures than frontal, temporal, or parietal lobe lesions.[11] In one study involving 112 patients with primary brain tumors, seizure rates with parietal, temporal, frontal, and occipital masses were reported to be 80%, 74%, 62%, and 0%, respectively.[12] Lesions involving the mesial temporal lobe, insula, and other paralimbic structures are more likely to give rise to intractable epilepsy than those located in other brain regions.[13],[14] Interestingly, patients with metastatic brain lesions often experience seizures less frequently than those who have primary brain masses.[9],[12],[15] Among different metastatic lesions, however, the seizure incidence also varies. Thus, seizures are quite common in metastatic melanoma with rates as high as 67%. This is thought to be related to the presence of multiple lesions, hemorrhage, and involvement of gray matter.[16],[17]

Epileptogenesis is also affected by the type of primary tumor. In DNETs where the incidence of seizures approaches 100%, underlying developmental structural abnormalities such as cortical dysplasia also contribute to the generation of seizures [Figure 2]. The relatively high incidence of seizures in low-grade lesions may be due to slowly developing focal abnormalities by mechanical or vascular changes that partially isolate brain regions. Seizures seen in high-grade lesions may be due to the rapid tissue damage caused by necrosis or hemosiderin deposition [Figure 3].[8], 10, [18],[19],[20],[21],[22] In general, the seizure onset tends to be from the peritumoral tissue. It can be at a significant distance from the tumor margin and is usually eccentric to the tumor.[23]
Figure 2: Patient with intractable epilepsy related to a left temporal dysembryoplastic neuroepithelial tumor (DNET). An adjacent but distinct area of focal cortical dysplasia was also noted on the histopathological examination of the surgical specimen. Coronal (a) and axial (b) FLAIR images showing the hyperintense mass. Hematoxylin and eosin (H and E) stain (c) demonstrating the typical glioneuronal elements of DNET; and, NeuN immunostaining (d) showing disorganization of neocortical lamination in focal cortical dysplasia

Click here to view
Figure 3: Patient with recurrent glioblastoma presenting with recurrent seizures despite multiple antiepileptic drugs. Post-contrast T1-weighted axial image (left) showing the large enhancing mass. Susceptibility-weighted imaging (right) demonstrates the tumoral and peritumoral hemosiderin deposit, which can often be implicated in the underlying pathogenesis in tumor-related epilepsy

Click here to view


Neurotransmitters

The exact mechanism by which tumors cause epileptogenesis in patients with brain tumors is unclear and is likely to be multifactorial and varied among different tumor types [Figure 1]. Animal studies of glioma have demonstrated increased glutamate (the principal excitatory neurotransmitter of the brain) release and neuronal hyperexcitability in the peritumoral region generating seizure activity.[24] Surrounding peritumoral cortex may be spontaneously hyperexcitable because astrocytes in the peritumoral region lose their ability to regulate extracellular glutamate.[25] A study of human tissues by Wolf et al., compared markers of glutamate and γ-aminobutyric acid (GABA; the principal inhibitory neurotransmitter of the brain) neurotransmission in resected tissues of patients affected by lesion-associated medically refractory epilepsy with similar lesions from patients who did not have chronic epilepsy. Specifically, they used immunohistochemistry to examine tissue slides for the presence of GABAA receptor, N-methyl-D-aspartate (NMDA) receptor subunit 1, and glutamate decarboxylase – the rate-limiting enzyme in the synthesis of GABA. The authors found that 73% of the specimens from patients with chronic epilepsy had distinct differences in these markers between the perilesional region and adjacent normal cortex.[20] These results suggest that the balance between excitatory and inhibitory transmission is disrupted between lesional and adjacent normal cortex, which may contribute to focal seizure generation.[20]

Another proposed mechanism by which brain tumors may induce seizures is through dysfunction of adenosine-mediated neurotransmission and dysregulation of adenosine kinase (ADK).[26],[27] A study published in 2012 by de Groot et al., examined surgically-excised tumor tissue, peritumoral cortex, and normal cortical tissues obtained on autopsy to compare ADK expression levels in patients with and without epilepsy. Their results showed a stronger immunoreactivity for ADK in tumoral and peritumoral tissues compared to normal cortex or white matter, and expression of ADK was significantly higher in infiltrated peritumoral tissue from patients with epilepsy than those without. These results suggest that upregulation of ADK in peritumoral tissue may contribute to tumor-related epilepsy.[26]

Blood–brain barrier disruption

Central nervous system (CNS) neurotransmission requires a tightly regulated microenvironment. The blood–brain barrier, at the level of the microvascular endothelium, is the major site for blood-CNS isolation or exchange of ions, neurotransmitters, macromolecules, neurotoxins, and nutrients.[28] It has been suggested that disruption of the blood–brain barrier may contribute to the pathogenesis of tumor-related epilepsy. Animal models have shown epileptiform activity involving both glutamatergic and GABAergic transmission after disruption of the blood–brain barrier.[29] Brain tumors can decrease the expression of junctional proteins such as claudin-1 and claudin-5.[30] Increased release of vascular endothelial growth factor (VEGF) has also been reported,[31],[32] which can exacerbate cerebral edema and contribute to seizure activity. Transforming growth factor beta (TGF-β) receptor stimulation may also contribute to epileptogenesis in these patients by causing accumulation of extracellular potassium and stimulation of NMDA-mediated hyperexcitability.[33] Further, blocking TGF-β receptors has been shown to decrease the likelihood of epileptogenesis in vivo.[34]

Gap junctions

Gap junctions allow adjacent cells to communicate, and changes in tumoral and peritumoral gap junctions may play a role in tumor-related epilepsy. Glial cells, especially astrocytes, have a greater number of gap junctions than neurons, and the major protein involved in astrocytic gap junctions is connexion 43 (CX43).[35] CX43 has been found to have increased expression in low-grade versus high-grade tumors and control brain tissue.[36],[37] This change was also seen in the peritumoral reactive astrocytes.[36] If this differentially increased expression of CX43 seen in low-grade gliomas contributes significantly to the development of epileptogenesis, it may explain the difference in seizure incidence seen between low- and high-grade gliomas. Moreover, studies have shown that blocking communication at the level of gap junctions may have anticonvulsant effects.[38],[39]

Molecular genetic changes

The genetic basis for some conditions that develop CNS tumors such as von Hippel–Lindau, tuberous sclerosis and neurofibromatosis are well understood. However, the contribution of genetic changes to the development of tumor-related epilepsy is not currently known. Genomic stability in tumors is decreased, which may lead to DNA strand breakage, rearrangements, mutations, and changes in gene expression. Some data exists to support the statement that downregulation of LGI1 (a tumor-suppressor gene) may lead to glioma progression,[40],[41] and mutations in this gene can cause epilepsy.[42],[43],[44] Other reports suggest that LGI1 may participate in cell-matrix interactions.[45] Mutations in the phosphatase and tensin homolog (PTEN) tumor suppressor gene are found commonly in glioblastoma. Interestingly, animal models examining mutations in PTEN also result in seizures and neuronal changes similar to those seen in Lhermitte–Duclos disease.[46] Several putative common pathways for the development of both glioma and tumor-related epilepsy have been reported, including changes in cytokines, neurotransmission, cell cycle control, DNA repair, apolipoprotein E, and neurotrophic factors.[47]

Peritumoral environmental changes

The microenvironment within and surrounding the brain tumor differs substantially from normal brain tissue.[48] Changes in tumoral and peritumoral neurotransmission have been already discussed. In addition, tumors often alter the permeability of new and existing vascular supply leading to breakdown of the blood–brain barrier. Growing intracranial lesions can lead to vasogenic edema, vascular insufficiency, inflammation, and altered metabolism.[49] Studies using magnetic resonance spectroscopy have demonstrated decreased N-acetyl aspartate in the perilesional cortex, which correlated with the degree of edema.[50] Tumoral hypoxia occurs from insufficient vascular supply and contributes to interstitial acidosis.[51],[52] This increases inward sodium currents [53],[54],[55] and NMDA receptor closure.[56] Increased peritumoral sodium and calcium can also contribute to neuronal hyperexcitability.[21],[22],[57],[58]


 » Clinical Manifestations Top


Not surprisingly, patients with tumor-related epilepsy can experience significant morbidity, cognitive deterioration, and decreased quality of life.[59],[60],[61],[62] Seizures exhibited by patients with brain tumors are either partial or secondarily generalized tonic–clonic seizures. Patients who experience focal seizures will have a clinical presentation that is dependent upon the exact tumor location. For example, frontal lobe tumors may cause tonic–clonic movements involving one extremity whereas occipital lobe lesions are likely to cause visual disturbances. Other findings can include abrupt changes in behavior, neurologic status, or sensations such as abnormal smell or taste. While tumor-associated seizures may vary widely between individuals, they are typically stereotypic for each patient. Auras usually represent focal seizures, and the seizure may be followed by a variable postictal phase that may include fatigue, Todd's paralysis, agitation, or even frank psychosis, especially in case of a cluster of seizures. In addition, patients with both primary and metastatic brain tumors can suffer from status epilepticus.[63] Status epilepticus is a medical emergency that carries high rates of mortality. A retrospective study by Cavaliere et al., examined 35 patients who experienced status epilepticus (SE) in the presence of a brain tumor.[63] In the study, 57% patients were taking AEDs at the time of SE, although 55% of the patients were subsequently found to have low AED serum levels. SE occurred at the time of tumor diagnosis in 29% of the patients. While 16% of the patients with glioma or metastatic disease experienced radiologically stable SE, approximately 60% of SE in patients with meningioma had a stable disease. The thirty-day mortality in this series was reportedly 23%.[63] When data from available, mostly retrospective, studies are examined, it appears that patients in SE with brain tumors have higher mortality rates than those who do not.[64] In total, approximately 7% of all cases of SE are caused by brain tumors.[65]

A 2009 observational study examined the medical records of 140 patients with brain tumors.[66] The authors report that, in their cohort of 33 patients with a low-grade glioma, 75 patients with a high-grade glioma, and 32 patients with other tumors (meningiomas, brain metastases, ependymomas), 99 patients developed epilepsy throughout the course of their disease. Among patients with a low-grade glioma, 69.7% initially presented with an epileptic seizure. This differed from those who had a high-grade glioma (52%) or other brain tumors (25%). Low-grade tumors tended to experience secondary generalized seizures (40%), whereas high-grade gliomas most commonly experienced simple partial seizures (38%). Patients with other tumor types also most commonly had simple partial seizures (78.6%), and SE was noted in 5% of all patients in this study. Interestingly, seizure frequency or development of seizures was not associated with tumor progression.[66] However, seizures at presentation may be a good prognostic sign for patients with GBM. Seizures later in the disease process, seizure recurrences, or SE during the course of the disease may be indicative of tumor progression.[67]


 » Medical Management Top


Seizures represent an important source of morbidity in patients afflicted with brain tumors.[68] Patients with brain tumors who have seizures are at increased risk of additional seizures,[2],[5],[18] and thus require treatment with anticonvulsants. The definition of epilepsy was modified in 2014 and now includes at least two unprovoked (or reflex) seizures occurring >24 hours apart or one unprovoked (or reflex) seizure and a probability of further seizures of at least 60% occurring over the next 10 years. In most instances, having a brain tumor and a single seizure now will qualify for diagnosis of epilepsy.[69] Hence, an unprovoked seizure in a patient with brain tumor should be treated with AEDs.

Choice of antiepileptic drugs

While limited number of randomized controlled trials have been performed to examine the superior efficacy of any one AED, it is generally recommended that clinicians begin treating patients with brain tumors experiencing seizures with newer AEDs such as levetiracetam, lamotrigine, lacosamide, topiramate, and pregabalin [Table 2].[133],[134][135],[136],[137],[138],[139],[140],[141],[142],[143],[145],[146],[147],[148],[149],[150] These medications tend to have fewer interactions with cytotoxic drugs (CTD) [Table 3][79],[94],[151],[152],[153] and lower side effect profiles.[70],[71],[72],[73],[74] A retrospective study examined 282 patients with supratentorial brain tumors receiving either levetiracetam or valproic acid (VPA) treatment.[75] In this study, the authors examined the rates of postoperative (<1 month) seizure rates as well as complications associated with AEDs. While the postoperative seizure rates were not significantly different between the two agents (7.8 and 6.5% respectively), complications were significantly higher in the VPA group compared to the levetiracetam group (26.8% versus 9.8%).[75] Small trials examining drug efficacy have been reported in the literature, and are also reviewed elsewhere.[1],[8],[59],[66],[76] A single-centre study of 140 patients with brain tumors reported that their most commonly used monotherapy agents were VPA (80%) and carbamazepine (12%). In this study, patients with a high-grade glioma required two AEDs in 63% of the patients versus 36% in patients with a low-grade glioma and in 29% of patients with other brain tumors. These data might suggest that seizures are more difficult to control medically in patients with a high-grade glioma.[66] Seizure treatment with VPA or with the combination of VPA and levetiracetam had the best rates of seizure freedom (52% and 59%, respectively).[66] In a small phase II randomized study, levetiracetam and pregabalin were shown to have efficacy as monotherapy for the treatment of tumor-related epilepsy, with rates of seizure freedom of 65% and 75%, respectively. Importantly, these drugs also have some of the lowest rates of drug interactions.[74] The type of seizure a patient experiences will also affect the AED choice.[77]
Table 2: Antiepileptic drugs used to treat tumor-related epilepsy

Click here to view
Table 3: AED metabolism and drug interactions

Click here to view


Common medical management problems in patients with brain tumors include seizures, venous thromboembolism, cognitive dysfunction, fatigue, and medication side effects.[78] As these patients with additional comorbidities often require many additional medications, treating these patients presents a therapeutic challenge. Patients with brain tumors often also benefit from treatment with chemotherapy. Minimizing drug–drug interactions is paramount in choosing the proper AED. A review by Yap et al., examined drug interactions specifically between AEDs and chemotherapeutics.[79] They identified carbamazepine, phenytoin, phenobarbital, and primidone as having substantial cytochrome P450 inducing effects, and VPA as having a major CYP450 inhibitory effect. These data serve to caution physicians in prescribing these AEDs for patients taking chemotherapeutics, increasing the need for careful monitoring of both AEDs and CTDs to ensure a therapeutic range without toxicity. As previously mentioned, some of the newer AEDs have fewer drug–drug interactions, and are thus more suitable to treat this patient population. Of course, AEDs themselves have side effects. In one series of patients with a malignant glioma who received long-term AED treatment with phenytoin, phenobarbital, carbamazepine, or valproate for seizures, 26% of the patients experienced rash whereas 14% experienced other adverse events.[2]

One frequently cited cause for refractory epilepsy is overexpression of proteins leading to multidrug resistance. These proteins, such as P-glycoprotein, MRP1, and MRP5, act at the level of the blood–brain barrier to actively transport lipophilic drugs (like many AEDs) through the capillary endothelium.[80],[81],[82],[83],[84] Interestingly, levetiracetam and VPA may not be substrates for these proteins, thus contributing to their better efficacy in these patients.[83],[85],[86]

Monotherapy versus combination therapy

Treating seizures with monotherapy compared to multidrug regimens offers a safer therapeutic window, increased compliance, and is more cost effective. However, additional agents are sometimes necessary if patients experience breakthrough seizures unresponsive to dose escalation and monotherapy switching. Unfortunately, this appears to be a common event in patients experiencing seizures with brain tumors. In one series examining 99 patients, 54 patients did not respond to a single AED therapy. In these patients, the most effective combination therapy appeared to be VPA and levetiracetam.[66] Despite optimal medical management, some studies report that as many as 60–70% of the patients will continue to have seizures.[2],[87] If seizures are not controlled with two AEDs, the addition of a third or fourth medication often has no benefit and these multiple drugs are utilized less frequently.[88] When more than one AED is utilized, a concept of rational polytherapy should be followed and a good working knowledge of the AED is necessary to avoid drug-related side effects and drug–drug interactions.[89]

Prophylaxis

While it is important to treat seizures in patients with primary or secondary brain tumors, prophylactic AED use is not recommended in the absence of a history of seizures.[5], 11, [90],[91],[92],[93] A Cochrane review has systematically examined the use of AEDs for seizure prophylaxis in patients with brain tumors.[90] In the study, the authors use first seizure occurrence as their primary outcome and adverse events as their secondary outcome. They included five randomized controlled trials totalling 404 participants. The review concluded that there was no difference in prevention of a first seizure between treatment (phenytoin, phenobarbital, or divalproex sodium) and control groups. As one might expect, the risk of adverse events was higher among those who received AEDs than those who did not (number needed to harm (NNH) 3, risk ratio (RR) 6.10, P = 0.046).[90] These findings suggest that AEDs should not be used routinely for the prophylaxis of seizures in patients with brain tumors because they are not effective in preventing seizures and, in fact, cause harm through adverse events. However, some data exists to suggest that metastatic melanoma might be an exception to this rule. Risk factors for increased rates of seizures, and thus the impetus for prophylactic therapy, included hemorrhage, and multiple supratentorial lesions.[17] The use of prophylactic treatment is discouraged not only because of their questionable efficacy in these patients, but because some AEDs are also known to interact with cytotoxic chemotherapeutics and steroids [Table 3].[94] In addition, AEDs themselves carry side effects that must be weighed against the potential benefit that the drug has to offer.


 » Oncologic Treatment and Epilepsy Top


Some data exists to show that treatment of the brain tumor itself with radiotherapy and/or chemotherapy may improve seizure control.[95],[96],[97],[98] Interestingly, this benefit does not necessarily correlate with changes in tumor burden on magnetic resonance imaging (MRI) or overall survival.[99],[100],[101] A systematic review of 24 studies examined the benefits of antitumor treatment with either radiotherapy or chemotherapy on rates of tumor-related epilepsy. While not all studies reported reductions in tumor burden or benefits of treatment, all studies did report improvement in seizure outcomes after antitumor treatment.[98],[101]

It is important that assessment of response to seizures from studies be well-defined and, ideally, uniform so that results may be compared between studies. Response to AED therapy in trials is usually defined as either a 50% reduction in seizure frequency from baseline or occasionally as seizure freedom. To this end, a seizure assessment tool has been proposed by Avila et al., that utilizes seizure classification, frequency, outcome, and severity to generate a composite score.[102] Assessment tools such as this may be used clinically to aid in identifying disease progression before radiographic evidence is available [103] and in identifying effective therapy.[102],[103],[104]


 » Surgical Management Top


As surgery is the mainstay of brain tumor treatment, surgical interventions are employed more readily in tumor-related epilepsy than in any other type of epilepsy. The surgical therapy in a vast majority of the patients is directed to the tumor and not towards treating epilepsy per se. In patients who have failed monotherapy with two first line agents, surgery may be recommended if there is a correctable lesion.[88],[105],[106] Patients with brain tumors usually fit in this category, and can benefit significantly from surgery. A properly thought out process ahead of tumor resection can provide a window of opportunity to address seizures during the same setting. This might not only cure or slow their tumor progression but might also decrease or eliminate seizures.[107],[108] A study of 207 patients with tumor-related epilepsy showed that 82% of the patients became seizure-free following surgery.[109] A short duration of seizures before surgery and a single seizure focus improves outcomes for seizure freedom.[109] A broader review of the literature consisting of 773 patients with tumor-related epilepsy reported within 20 series shows that approximately 71% of patients will achieve postoperative seizure freedom. This success was found to be proportionately higher among those who underwent gross total resection versus subtotal resection of the tumor.[110] In a small series examining 36 patients with mesial temporal lobe tumors and seizures, most being resistant to AEDs, older patients, a large tumor size, and invasion beyond the mesial temporal lobe were associated with poor outcomes. Interestingly, they also found that a short duration of seizures was associated with a more aggressive disease, and those patients who had a mesial temporal lobe tumor were associated with chronic epilepsy.[111] Epileptic patients who have DNETs or gangliogliomas are often good candidates for surgery because their epilepsy is exceptionally resistant to medical management.[59],[108]

Studies using EEG mapping have shown that structural lesions can cause epileptic foci in the neighbouring or even remote areas of the brain.[23],[112] Maximum resection of the lesion offers the best chance for seizure freedom, though subtotal resections that include the lesion or epileptic focus will likely benefit the patient. Careful mapping is required to identify individuals in which the lesion may not be the primary epileptogenic focus.[112] Approaching these patients with epilepsy surgery may be required to achieve maximal seizure freedom.[23] Seizures occurring in patients with brain tumors can also be treated by addressing the mass regardless of whether or not the seizures are controlled with AEDs.[59] In particular, improved seizure outcomes have been associated with finding a single lesion on imaging, a short duration of seizure disorder prior to surgery, finding a single focus on electroencephalography (EEG), and complete tumor resection.[113] A systematic review reported that 87% of the patients who underwent gross total resection were seizure free versus 55% of those who had a subtotal resection.[114] Of course, surgical planning must still weigh the potential benefits of surgery against the possible postsurgical morbidity. Surgery itself is not a benign treatment modality. Seizures may occur in the early postoperative period in approximately 15% of patients who undergo supratentorial tumor resection in addition to the other risks of surgery.[115]

Tumors associated with long-term intractable epilepsy, for example, those in the mesial temporal lobe or insula, and childhood lesions such as glioneuronal tumors should be given additional consideration for an early surgical intervention not only for its reported superior treatment efficacy but also for achieving an increased quality of life and patient satisfaction.[109], 114, [116],[117],[118],[119],[120],[121] Not surprisingly, the extent of surgical resection may correlate with the degree of seizure freedom postoperatively in these patients as well as those with many additional tumor types examined in other studies.[110],[114],[118],[122],[123] Other factors that were found to predict postoperative seizure freedom are the time until surgery, localization of foci, concordant MRI and EEG findings, and lack of secondary generalization.[124]

Surgical management of patients with tumor-related epilepsy begins with attempting to localize the seizure focus with routine scalp EEG. EEG measures the electrical field in the scalp that is generated by groups of neurons within the brain. Often, this provides insufficient data to allow an accurate localization for surgical planning.[125] Mapping with invasive EEG (iEEG) monitoring leads to improved localization and outcomes,[126] and includes those procedures which place electrodes (peg electrode, subdural grid, strip electrode, depth electrode) closer to the surface of the brain [Figure 4]. Electrocorticography (ECoG) uses subdural or depth electrodes to record activity directly from the brain. This technique may be used intraoperatively for short periods of time or extraoperatively for hours to days [Figure 4]. Stereoencephalography (SEEG) is a technique that uses multiple depth electrodes to record activity within the brain. The use of iEEG is recommended when scalp EEG is insufficient (e.g., shows bilateral ictal discharges, excessive artefacts); there is localization disagreement between imaging, scalp EEG, and neuropsychological testing; there is involvement of the eloquent cortex; lateralizing of the dominant epileptogenic temporal lobe is required.[125],[127] After electrodes are implanted, patients are kept on long-term video EEG monitoring until several seizures (3–5) are captured. This allows for the definition of the area of seizure onset as well as any surrounding tissue capable of generating or maintaining seizures.[128] Surgery may then proceed to remove the tumor and the associated seizure foci. This may be accomplished through the use of ECoG or an awake craniotomy if the area involves the eloquent cortex.[128]
Figure 4: A 34-year-old man presenting with new-onset seizures related to a large nonenhancing left frontal mass. Coronal T2-weighted (a) and axial FLAIR (b) images. The mass is outlined and segmented in each slice (c) and later stacked to create a three dimensional (3D) map of the tumor. Intraoperative image (d) of the subdural grid during the second stage of surgery (resection margin outlined by suture) A post-implant CT scan scout image (e) showing the intracranial electrode placement. 3D-rendering of the MRI fused with post-implant CT scan (f) depicting brain surface superimposed with the subdural grid electrodes. Tumor (g) shown in red through a semi-transparent brain surface. The epileptogenic zone determined by long-term extraoperative intracranial EEG recording is shown in yellow, and overlaps only partially with the tumor and extends beyond the tumor margin in an eccentric manner

Click here to view



 » Summary Top


In conclusion, current data supports the use of AEDs for the treatment of tumor-related epilepsy. Therapy should begin with the use of a newer AED as monotherapy [Table 2]. If this treatment fails, a second monotherapy may be tried. Subsequent attempts to control seizures might include combinations of first or second line agents. Surgical intervention may be necessary to obtain additional seizure relief if the medical management continues to fail. Factors associated with postoperative seizure freedom are the time until surgery, localization of foci, concordant MRI and EEG findings, and lack of secondary generalization. Patients with brain tumor-related epilepsy should be referred to an epilepsy center early in the course of the disease to maximize the likelihood of seizure freedom and improve the quality of life.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest

 
 » References Top

1.
Avila EK, Graber J. Seizures and epilepsy in cancer patients. Curr Neurol Neurosci Rep 2010;10:60-7.  Back to cited text no. 1
    
2.
Moots PL, Maciunas RJ, Eisert DR, Parker RA, Laporte K, Abou-Khalil B. The course of seizure disorders in patients with malignant gliomas. Arch Neurol 1995;52:717-24.  Back to cited text no. 2
    
3.
Cohen N, Strauss G, Lew R, Silver D, Recht L. Should prophylactic anticonvulsants be administered to patients with newly-diagnosed cerebral metastases? A retrospective analysis. J Clin Oncol 1988;6:1621-4.  Back to cited text no. 3
    
4.
Herman ST. Epilepsy after brain insult targeting epileptogenesis. Neurology 2002;59:S21-S6.  Back to cited text no. 4
    
5.
Glantz M, Cole B, Forsyth P, Recht L, Wen P, Chamberlain M, et al. Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;54:1886-93.  Back to cited text no. 5
    
6.
Olafsson E, Ludvigsson P, Hesdorffer D, Kjartansson O, Hauser WA, Gudmundsson G. Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: A prospective study. Lancet Neurol 2005;4:627-34.  Back to cited text no. 6
    
7.
You G, Sha Z, Jiang T. The pathogenesis of tumor-related epilepsy and its implications for clinical treatment. Seizure 2012;21:153-9.  Back to cited text no. 7
    
8.
van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: Epidemiology, mechanisms, and management. Lancet Neurol 2007;6:421-30.  Back to cited text no. 8
    
9.
Lote K, Stenwig A, Skullerud K, Hirschberg H. Prevalence and prognostic significance of epilepsy in patients with gliomas. Eur J Cancer 1998;34:98-102.  Back to cited text no. 9
    
10.
Villemure J-G, de Tribolet N. Epilepsy in patients with central nervous system tumors. Curr Opin Neurol 1996;9:424-8.  Back to cited text no. 10
    
11.
Sirven JI, Wingerchuk DM, Drazkowski JF, Lyons MK, Zimmerman RS. Seizure prophylaxis in patients with brain tumors: A meta-analysis. Mayo Clin Proc 2004;79:1489-94.  Back to cited text no. 11
    
12.
Lynam LM, Lyons MK, Drazkowski JF, Sirven JI, Noe KH, Zimmerman RS, et al. Frequency of seizures in patients with newly diagnosed brain tumors: A retrospective review. Clin Neurol Neurosurg 2007;109:634-8.  Back to cited text no. 12
    
13.
Duffau H, Capelle L, Lopes M, Bitar A, Sichez J-P, Van Effenterre R. Medically intractable epilepsy from insular low-grade gliomas: Improvement after an extended lesionectomy. Acta Neurochir 2002;144:563-73.  Back to cited text no. 13
    
14.
Mittal S, Montes JL, Farmer JP, Rosenblatt B, Dubeau F, Andermann F, et al. Long-term outcome after surgical treatment of temporal lobe epilepsy in children. J Neurosurg 2005;103:401-12.  Back to cited text no. 14
    
15.
Pace A, Bove L, Innocenti P, Pietrangeli A, Carapella C, Oppido P, et al. Epilepsy and gliomas: Incidence and treatment in 119 patients. J Exp Clin Cancer Res 1998;17:479-82.  Back to cited text no. 15
    
16.
Oberndorfer S, Schmal T, Lahrmann H, Urbanits S, Lindner K, Grisold W. The frequency of seizures in patients with primary brain tumors or cerebral metastases. An evaluation from the Ludwig Boltzmann Institute of Neuro-Oncology and the Department of Neurology, Kaiser Franz Josef Hospital, Vienna. Wien Klin Wochenschr 2002;114:911-6.  Back to cited text no. 16
    
17.
Goldlust S, Hsu M, Lassman A, Panageas K, Avila E. Seizure prophylaxis and melanoma brain metastases. J Neurooncol 2012;108:109-14.  Back to cited text no. 17
    
18.
Cascino GD. Epilepsy and brain tumors: Implications for treatment. Epilepsia 1990;31:S37-S44.  Back to cited text no. 18
    
19.
Riva M. Brain tumoral epilepsy: A review. Neurol Sci 2005;26:s40-s2.  Back to cited text no. 19
    
20.
Wolf HK, Roos D, Blümcke I, Pietsch T, Wiestler OD. Perilesional neurochemical changes in focal epilepsies. Acta Neuropathol 1996;91:376-84.  Back to cited text no. 20
    
21.
Haacke EM, Mittal S, Wu Z, Neelavalli J, Cheng YC. Susceptibility-weighted imaging: Technical aspects and clinical applications, part 1. AJNR Am J Neuroradiol 2009;30:19-30.  Back to cited text no. 21
    
22.
Mittal S, Wu Z, Neelavalli J, Haacke EM. Susceptibility-weighted imaging: Technical aspects and clinical applications, part 2. AJNR Am J Neuroradiol 2009;30:232-52.  Back to cited text no. 22
    
23.
Mittal S, Barkmeier D, Hua J, Pai D, Fuerst D, Basha M, et al. Intracranial EEG analysis in tumor-related epilepsy: Evidence of distant epileptic abnormalities. Clin Neurophysiol 2016;127:238-44.  Back to cited text no. 23
    
24.
Buckingham SC, Campbell SL, Haas BR, Montana V, Robel S, Ogunrinu T, et al. Glutamate release by primary brain tumors induces epileptic activity. Nature Med 2011;17:1269-74.  Back to cited text no. 24
    
25.
Buckingham SC, Robel S. Glutamate and tumor-associated epilepsy: Glial cell dysfunction in the peritumoral environment. Neurochem Int 2013;63:696-701.  Back to cited text no. 25
    
26.
de Groot M, Iyer A, Zurolo E, Anink J, Heimans JJ, Boison D, et al. Overexpression of ADK in human astrocytic tumors and peritumoral tissue is related to tumor-associated epilepsy. Epilepsia 2012;53:58-66.  Back to cited text no. 26
    
27.
Boison D, Stewart K-A. Therapeutic epilepsy research: From pharmacological rationale to focal adenosine augmentation. Biochem Pharmacol 2009;78:1428-37.  Back to cited text no. 27
    
28.
Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood–brain barrier. Neurobiol Dis 2010;37:13-25.  Back to cited text no. 28
    
29.
Seiffert E, Dreier JP, Ivens S, Bechmann I, Tomkins O, Heinemann U, et al. Lasting blood-brain barrier disruption induces epileptic focus in the rat somatosensory cortex. J Neurosci 2004;24:7829-36.  Back to cited text no. 29
    
30.
Liebner S, Fischmann A, Rascher G, Duffner F, Grote EH, Kalbacher H, et al. Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol 2000;100:323-31.  Back to cited text no. 30
    
31.
Lamszus K, Laterra J, Westphal M, Rosen EM. Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. Int J Dev Neurosci 1999;17:517-30.  Back to cited text no. 31
    
32.
Strugar JG, Criscuolo GR, Rothbart D, Harrington WN. Vascular endothelial growth/permeability factor expression in human glioma specimens: Correlation with vasogenic brain edema and tumor-associated cysts. J Neurosurg 1995;83:682-9.  Back to cited text no. 32
    
33.
Ivens S, Kaufer D, Flores LP, Bechmann I, Zumsteg D, Tomkins O, et al. TGF-β receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis. Brain 2007;130:535-47.  Back to cited text no. 33
    
34.
Cacheaux LP, Ivens S, David Y, Lakhter AJ, Bar-Klein G, Shapira M, et al. Transcriptome profiling reveals TGF-β signaling involvement in epileptogenesis. J Neurosci 2009;29:8927-35.  Back to cited text no. 34
    
35.
Nemani VM, Binder DK. Emerging role of gap junctions in epilepsy. Histol Histopathol 2005;20:253-9.  Back to cited text no. 35
    
36.
Aronica E, Gorter JA, Jansen GH, Leenstra S, Yankaya B, Troost D. Expression of connexin 43 and connexin 32 gap-junction proteins in epilepsy-associated brain tumors and in the perilesional epileptic cortex. Acta Neuropathol 2001;101:449-59.  Back to cited text no. 36
    
37.
Soroceanu L, Manning TJ, Sontheimer H. Reduced expression of connexin-43 and functional gap junction coupling in human gliomas. Glia 2001;33:107-17.  Back to cited text no. 37
    
38.
Jahromi SS, Wentlandt K, Piran S, Carlen PL. Anticonvulsant actions of gap junctional blockers in an in vitro seizure model. J Neurophysiol 2002;88:1893-902.  Back to cited text no. 38
    
39.
Juszczak GR, Swiergiel AH. Properties of gap junction blockers and their behavioural, cognitive and electrophysiological effects: Animal and human studies. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:181-98.  Back to cited text no. 39
    
40.
Kunapuli P, Chitta KS, Cowell JK. Suppression of the cell proliferation and invasion phenotypes in glioma cells by the LGI1 gene. Oncogene 2003;22:3985-91.  Back to cited text no. 40
    
41.
Besleaga R, Montesinos-Rongen M, Perez-Tur J, Siebert R, Deckert M. Expression of the LGI1 gene product in astrocytic gliomas: Downregulation with malignant progression. Virchows Archiv 2003;443:561-4.  Back to cited text no. 41
    
42.
Kalachikov S, Evgrafov O, Ross B, Winawer M, Barker-Cummings C, Boneschi FM, et al. Mutations in LGI1 cause autosomal-dominant partial epilepsy with auditory features. Nature Genet 2002;30:335-41.  Back to cited text no. 42
    
43.
Morante-Redolat JM, Gorostidi-Pagola A, Piquer-Sirerol S, Sáenz A, Poza JJ, Galán J, et al. Mutations in the LGI1/Epitempin gene on 10q24 cause autosomal dominant lateral temporal epilepsy. Human Mol Genet 2002;11:1119-28.  Back to cited text no. 43
    
44.
Gu W, Brodtkorb E, Steinlein OK. LGI1 is mutated in familial temporal lobe epilepsy characterized by aphasic seizures. Ann Neurol 2002;52:364-7.  Back to cited text no. 44
    
45.
Piepoli T, Jakupoglu C, Gu W, Lualdi E, Suarez-Merino B, Poliani PL, et al. Expression studies in gliomas and glial cells do not support a tumor suppressor role for LGI1. Neurooncology 2006;8:96-108.  Back to cited text no. 45
    
46.
Backman SA, Stambolic V, Suzuki A, Haight J, Elia A, Pretorius J, et al. Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. Nature Genet 2001;29:396-403.  Back to cited text no. 46
    
47.
Berntsson SG, Malmer B, Bondy ML, Qu M, Smits A. Tumor-associated epilepsy and glioma: Are there common genetic pathways? Acta Oncol 2009;48:955-63.  Back to cited text no. 47
    
48.
Beaumont A, Whittle I. The pathogenesis of tumour associated epilepsy. Acta Neurochir 2000;142:1-15.  Back to cited text no. 48
    
49.
Shamji MF, Fric-Shamji EC, Benoit BG. Brain tumors and epilepsy: Pathophysiology of peritumoral changes. Neurosurg Rev 2009;32:275-85.  Back to cited text no. 49
    
50.
Chernov MF, Kubo O, Hayashi M, Izawa M, Maruyama T, Usukura M, et al. Proton MRS of the peritumoral brain. J Neurol Sci 2005;228:137-42.  Back to cited text no. 50
    
51.
Wang J, Klem J, Wyrick JB, Ozawa T, Cunningham E, Golinveaux J, et al. Detection of hypoxia in human brain tumor xenografts using a modified comet assay. Neoplasia 2003;5:288-96.  Back to cited text no. 51
    
52.
Zagzag D, Nomura M, Friedlander DR, Blanco C, Gagner JP, Nomura N, et al. Geldanamycin inhibits migration of glioma cells in vitro: A potential role for hypoxia-inducible factor (HIF-1α) in glioma cell invasion. J Cell Physiol 2003;196:394-402.  Back to cited text no. 52
    
53.
Berdiev BK, Xia J, McLean LA, Markert JM, Gillespie GY, Mapstone TB, et al. Acid-sensing ion channels in malignant gliomas. J Biol Chem 2003;278:15023-34.  Back to cited text no. 53
    
54.
Bubien JK, Keeton DA, Fuller CM, Gillespie GY, Reddy AT, Mapstone TB, et al. Malignant human gliomas express an amiloride-sensitive Na+ conductance. Am J Physiol 1999;276:C1405-C10.  Back to cited text no. 54
    
55.
Kraft R, Basrai D, Benndorf K, Patt S. Serum deprivation and NGF induce and modulate voltage-gated Na+ currents in human astrocytoma cell lines. Glia 2001;34:59-67.  Back to cited text no. 55
    
56.
Dravid SM, Erreger K, Yuan H, Nicholson K, Le P, Lyuboslavsky P, et al. Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block. J Physiol 2007;581:107-28.  Back to cited text no. 56
    
57.
Hossmann K, Seo K, Szymas J, Wechsler W. Quantitative analysis of experimental peritumoral edema in cats. Adv Neurol 1989;52:449-58.  Back to cited text no. 57
    
58.
Wu Z, Mittal S, Kish K, Yu Y, Hu J, Haacke EM. Identification of calcification with MRI using susceptibility-weighted imaging: A case study. J Magn Reson Imaging 2009;29:177-82.  Back to cited text no. 58
    
59.
Rudà R, Trevisan E, Soffietti R. Epilepsy and brain tumors. Curr Opin Oncol 2010;22:611-20.  Back to cited text no. 59
    
60.
Sheth RD. Adolescent issues in epilepsy. J Child Neurol 2002;17:2S23-2S7.  Back to cited text no. 60
    
61.
Taphoorn MJ, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol 2004;3:159-68.  Back to cited text no. 61
    
62.
Zaatreh MM, Firlik KS, Spencer DD, Spencer SS. Temporal lobe tumoral epilepsy: Characteristics and predictors of surgical outcome. Neurology 2003;61:636-41.  Back to cited text no. 62
    
63.
Cavaliere R, Farace E, Schiff D. Clinical implications of status epilepticus in patients with neoplasms. Arch Neurol 2006;63:1746-9.  Back to cited text no. 63
    
64.
Arik Y, Leijten FS, Seute T, Robe PA, Snijders TJ. Prognosis and therapy of tumor-related versus non-tumor-related status epilepticus: A systematic review and meta-analysis. BMC Neurol 2014;14:1.  Back to cited text no. 64
    
65.
DeLorenzo RJ, Pellock JM, Towne AR, Boggs JG. Epidemiology of status epilepticus. J Clin Neurophysiol 1995;12:316.  Back to cited text no. 65
    
66.
van Breemen MS, Rijsman R, Taphoorn M, Walchenbach R, Zwinkels H, Vecht CJ. Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol 2009;256:1519-26.  Back to cited text no. 66
    
67.
Toledo M, Sarria-Estrada S, Quintana M, Maldonado X, Martinez-Ricarte F, Rodon J, et al. Prognostic implications of epilepsy in glioblastomas. Clin Neurol Neurosurg 2015;139:166-71.  Back to cited text no. 67
    
68.
Taphoorn MJ. Neurocognitive sequelae in the treatment of low-grade gliomas. Semin Oncol 2003;30(Suppl 19):45-8.  Back to cited text no. 68
    
69.
Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: A practical clinical definition of epilepsy. Epilepsia 2014;55:475-82.  Back to cited text no. 69
    
70.
Rosati A, Buttolo L, Stefini R, Todeschini A, Cenzato M, Padovani A. Efficacy and safety of levetiracetam in patients with glioma: A clinical prospective study. Arch Neurol 2010;67:343-6.  Back to cited text no. 70
    
71.
Usery JB, Michael II LM, Sills AK, Finch CK. A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures. J Neurooncol 2010;99:251-60.  Back to cited text no. 71
    
72.
Maschio M, Dinapoli L, Gomellini S, Ferraresi V, Sperati F, Vidiri A, et al. Antiepileptics in brain metastases: Safety, efficacy and impact on life expectancy. J Neurooncol 2010;98:109-16.  Back to cited text no. 72
    
73.
Saria MG, Corle C, Hu J, Rudnick JD, Phuphanich S, Mrugala MM, et al. Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: Clinical article. J Neurosurg 2013;118:1183-7.  Back to cited text no. 73
    
74.
Rossetti AO, Jeckelmann S, Novy J, Roth P, Weller M, Stupp R. Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. Neurooncology 2003;30(6 Suppl):45-8.  Back to cited text no. 74
    
75.
Lee YJ, Kim T, Bae SH, Kim YH, Han JH, Yun CH, et al. Levetiracetam compared with valproic acid for the prevention of postoperative seizures after supratentorial tumor surgery: A retrospective chart review. CNS drugs 2013;27:753-9.  Back to cited text no. 75
    
76.
Vecht CJ, van Breemen M. Optimizing therapy of seizures in patients with brain tumors. Neurology 2006;67:S10-S3.  Back to cited text no. 76
    
77.
Asadi-Pooya AA, Sperling MR. Antiepileptic Drugs: A Clinician's Manual: Oxford University Press, Incorporated; 2016.  Back to cited text no. 77
    
78.
Wen PY, Schiff D, Kesari S, Drappatz J, Gigas DC, Doherty L. Medical management of patients with brain tumors. J Neurooncol 2006;80:313-32.  Back to cited text no. 78
    
79.
Yap KY-L, Chui WK, Chan A. Drug interactions between chemotherapeutic regimens and antiepileptics. Clin Ther 2008;30:1385-407.  Back to cited text no. 79
    
80.
Löscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 2002;301:7-14.  Back to cited text no. 80
    
81.
Calatozzolo C, Gelati M, Ciusani E, Sciacca F, Pollo B, Cajola L, et al. Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 AND GST-π in human glioma. J Neurooncol 2005;74:113-21.  Back to cited text no. 81
    
82.
Aronica E, Gorter J, Jansen G, Van Veelen C, Van Rijen P, Leenstra S, et al. Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: Focal cortical dysplasia and glioneuronal tumors. Neuroscience 2003;118:417-29.  Back to cited text no. 82
    
83.
Löscher W. Drug transporters in the epileptic brain. Epilepsia 2007;48:8-13.  Back to cited text no. 83
    
84.
Luna-Tortós C, Fedrowitz M, Löscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 2008;55:1364-75.  Back to cited text no. 84
    
85.
Baltes S, Fedrowitz M, Tortós CL, Potschka H, Löscher W. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther 2007;320:331-43.  Back to cited text no. 85
    
86.
Potschka H, Baltes S, Löscher W. Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats. Epilepsy Res 2004;58:85-91.  Back to cited text no. 86
    
87.
Hildebrand J, Lecaille C, Perennes J, Delattre JY. Epileptic seizures during follow-up of patients treated for primary brain tumors. Neurology 2005;65:212-5.  Back to cited text no. 87
    
88.
Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-9.  Back to cited text no. 88
    
89.
Brodie MJ, Sills GJ. Combining antiepileptic drugs—rational polytherapy? Seizure 2011;20:369-75.  Back to cited text no. 89
    
90.
Tremont-Lukats IW, Ratilal BO, Armstrong T, Gilbert MR. Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev 2008;2:CD004424.  Back to cited text no. 90
    
91.
Mikkelsen T, Paleologos NA, Robinson PD, Ammirati M, Andrews DW, Asher AL, et al. The role of prophylactic anticonvulsants in the management of brain metastases: A systematic review and evidence-based clinical practice guideline. J Neurooncol 2010;96:97-102.  Back to cited text no. 91
    
92.
Sughrue ME, Rutkowski MJ, Chang EF, Shangari G, Kane AJ, McDermott MW, et al. Postoperative seizures following the resection of convexity meningiomas: Are prophylactic anticonvulsants indicated? Clinical article. J Neurosurg 2011;114:705-9.  Back to cited text no. 92
    
93.
Forsyth PA, Weaver S, Fulton D, Brasher P, Sutherland G, Stewart D, et al. Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci 2003;30:106-12.  Back to cited text no. 93
    
94.
Patsalos PN, Fröscher W, Pisani F, Van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia 2002;43:365-85.  Back to cited text no. 94
    
95.
Rossi G, Scerrati M, Roselli R. Epileptogenic cerebral low-grade tumors: Effect of interstitial stereotactic irradiation on seizures. Stereotact Func Neurosurg 1986;48:127-32.  Back to cited text no. 95
    
96.
Rogers LR, Morris HH, Lupica K. Effect of cranial irradiation on seizure frequency in adults with low-grade astrocytoma and medically intractable epilepsy. Neurology 1993;43:1599-601.  Back to cited text no. 96
    
97.
Schröttner O, Unger F, Eder H, Feichtinger M, Pendl G. Gamma-knife radiosurgery of mesiotemporal tumour epilepsy observations and long term results. Acta Neurochir Suppl 2002;84:49-55.  Back to cited text no. 97
    
98.
Sherman JH, Moldovan K, Yeoh HK, Starke RM, Pouratian N, Shaffrey ME, et al. Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas: Clinical article. J Neurosurg 2011;114:1617-21.  Back to cited text no. 98
    
99.
Rudà R, Magliola U, Bertero L, Trevisan E, Bosa C, Mantovani C, et al. Seizure control following radiotherapy in patients with diffuse gliomas: A retrospective study. Neuro Oncol 2013;15:1739-49.  Back to cited text no. 99
    
100.
Van den Bent M, Afra D, De Witte O, Hassel MB, Schraub S, Hoang-Xuan K, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: The EORTC 22845 randomised trial. Lancet 2005;366:985-90.  Back to cited text no. 100
    
101.
Koekkoek JA, Kerkhof M, Dirven L, Heimans JJ, Reijneveld JC, Taphoorn MJ. Seizure outcome after radiotherapy and chemotherapy in low-grade glioma patients: A systematic review. Neuro Oncol 2015;17:924-34.  Back to cited text no. 101
    
102.
Avila EK, Chamberlain M, Schiff D, Reijneveld JC, Armstrong TS, Ruda R, et al. Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. Neuro Oncol 2017;19:12-21.  Back to cited text no. 102
    
103.
You G, Sha ZY, Yan W, Zhang W, Wang YZ, Li S-W, et al. Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: A clinicopathological study. Neuro Oncol 2012;14:230-41.  Back to cited text no. 103
    
104.
Koekkoek JA, Dirven L, Heimans JJ, Postma TJ, Vos MJ, Reijneveld JC, et al. Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide. J Neurooncol 2016;126:347-54.  Back to cited text no. 104
    
105.
Engel Jr J. Surgery for seizures. N Eng J Med 1996;334:647-53.  Back to cited text no. 105
    
106.
Wieser HG. Epilepsy surgery: Past, present and future. Seizure 1998;7:173-84.  Back to cited text no. 106
    
107.
Panda S, Radhakrishnan VV, Radhakrishnan K, Rao RM, Sarma SP. Electro-clinical characteristics and postoperative outcome of medically refractory tumoral temporal lobe epilepsy. Neurol India 2005;53:66.  Back to cited text no. 107
[PUBMED]  [Full text]  
108.
Rheims S, Ducray F, Ryvlin P. Choosing the tumoral epilepsy surgery candidate. Epilepsia 2013;54:91-6.  Back to cited text no. 108
    
109.
Luyken C, Blümcke I, Fimmers R, Urbach H, Elger CE, Wiestler OD, et al. The spectrum of long-term epilepsy–associated tumors: Long-term seizure and tumor outcome and neurosurgical aspects. Epilepsia 2003;44:822-30.  Back to cited text no. 109
    
110.
Englot DJ, Berger MS, Barbaro NM, Chang EF. Predictors of seizure freedom after resection of supratentorial low-grade gliomas: A review. J Neurosurg 2011;115:240-4.  Back to cited text no. 110
    
111.
PHi JH, CHung CK. Brain tumors in the mesial temporal lobe: Long-term oncological outcome. Neurosurg Focus 2009;27:E5.  Back to cited text no. 111
    
112.
Awad IA, Rosenfeld J, Ahl J, Hahn JF, Lüders H. Intractable epilepsy and structural lesions of the brain: Mapping, resection strategies, and seizure outcome. Epilepsia 1991;32:179-86.  Back to cited text no. 112
    
113.
Chan CH, Bittar RG, Davis GA, Kalnins RM, Fabinyi GC. Long-term seizure outcome following surgery for dysembryoplastic neuroepithelial tumor. J Neurosurg 2006;104:62-9.  Back to cited text no. 113
    
114.
Englot DJ, Berger MS, Barbaro NM, Chang EF. Factors associated with seizure freedom in the surgical resection of glioneuronal tumors. Epilepsia 2012;53:51-7.  Back to cited text no. 114
    
115.
De Santis A, Villani R, Sinisi M, Stocchetti N, Perucca E. Add-on phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors: A randomized controlled study. Epilepsia 2002;43:175-82.  Back to cited text no. 115
    
116.
Ramantani G, Kadish NE, Anastasopoulos C, Brandt A, Wagner K, Strobl K, et al. Epilepsy surgery for glioneuronal tumors in childhood: Avoid loss of time. Neurosurgery 2014;74:648-57.  Back to cited text no. 116
    
117.
Benifla M, Rutka JT, Otsubo H, Lamberti-Pasculli M, Elliott I, Sell E, et al. Long-term seizure and social outcomes following temporal lobe surgery for intractable epilepsy during childhood. Epilepsy Res 2008;82:133-8.  Back to cited text no. 117
    
118.
Southwell DG, Garcia PA, Berger MS, Barbaro NM, Chang EF. Long-term seizure control outcomes after resection of gangliogliomas. Neurosurgery 2012;70:1406-14.  Back to cited text no. 118
    
119.
Phi JH, Kim SK, Cho BK, Lee SY, Park SY, Park Sj, et al. Long-term surgical outcomes of temporal lobe epilepsy associated with low-grade brain tumors. Cancer 2009;115:5771-9.  Back to cited text no. 119
    
120.
Packer RJ, Sutton LN, Patel KM, Duhaime A-C, Schiff S, Weinstein SR, et al. Seizure control following tumor surgery for childhood cortical low-grade gliomas. J Neurosurg 1994;80:998-1003.  Back to cited text no. 120
    
121.
Sandberg DI, Ragheb J, Dunoyer C, Bhatia S, Olavarria G, Morrison G. Surgical outcomes and seizure control rates after resection of dysembryoplastic neuroepithelial tumors. Neurosurg Focus 2005;18:1-4.  Back to cited text no. 121
    
122.
Englot DJ, Han SJ, Berger MS, Barbaro NM, Chang EF. Extent of surgical resection predicts seizure freedom in low-grade temporal lobe brain tumors. Neurosurgery 2012;70:921-8.  Back to cited text no. 122
    
123.
Bonney PA, Glenn CA, Ebeling PA, Conner AK, Boettcher LB, Cameron DM, et al. Seizure freedom rates and prognostic indicators after resection of gangliogliomas: A review. World Neurosurg 2015;84:1988-96.  Back to cited text no. 123
    
124.
Englot DJ, Chang EF. Rates and predictors of seizure freedom in resective epilepsy surgery: An update. Neurosurg review 2014;37:389-405.  Back to cited text no. 124
    
125.
Shah AK, Mittal S. Invasive electroencephalography monitoring: Indications and presurgical planning. Ann Indian Acad Neurol 2014;17:S89.  Back to cited text no. 125
[PUBMED]  [Full text]  
126.
Jennum P, Dhuna A, Davies K, Fiol M, Maxwell R. Outcome of resective surgery for intractable partial epilepsy guided by subdural electrode arrays. Acta Neurol Scand 1993;87:434-7.  Back to cited text no. 126
    
127.
Voorhies J, Cohen-Gadol A. Techniques for placement of grid and strip electrodes for intracranial epilepsy surgery monitoring: Pearls and pitfalls. Surg Neurol Int 2013;4:98.  Back to cited text no. 127
[PUBMED]  [Full text]  
128.
Mittal S, Shah AK. Surgery for Epilepsy. Textbook of Contemporary Neurosurgery. Jaypee Brothers, Medical Publishers Pvt. Limited; 2012. p. 1603-42.  Back to cited text no. 128
    
129.
Lieu A-S, Howng S-L. Intracranial meningiomas and epilepsy: Incidence, prognosis and influencing factors. Epilepsy Res 1999;38:45-52.  Back to cited text no. 129
    
130.
Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol 2015;17:iv1-iv62.  Back to cited text no. 130
    
131.
Sanai N, Chang S, Berger MS. Low-grade gliomas in adults: A review. J Neurosurg 2011:1-18.  Back to cited text no. 131
    
132.
Villano J, Koshy M, Shaikh H, Dolecek TA, McCarthy B. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer 2011;105:1414-8.  Back to cited text no. 132
    
133.
Nolan SJ, Marson AG, Weston J, Tudur Smith C. Carbamazepine versus phenytoin monotherapy for epilepsy: An individual participant data review. Cochrane Database Syst Rev 2015;8:CD001911.  Back to cited text no. 133
    
134.
Nolan SJ, Marson AG, Weston J, Tudur Smith C. Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonic seizures: An individual participant data review. Cochrane Database Syst Rev 2016;4:CD001769.  Back to cited text no. 134
    
135.
Chadwick D, Anhut H, Greiner M, Alexander J, Murray G, Garofalo E, et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. Neurology 1998;51:1282-8.  Back to cited text no. 135
    
136.
French J, Glue P, Friedman D, Almas M, Yardi N, Knapp L, et al. Adjunctive pregabalin vs gabapentin for focal seizures Interpretation of comparative outcomes. Neurology 2016;87:1242-9.  Back to cited text no. 136
    
137.
Brodie MJ, Overstall PW, Giorgi L, Group ULES. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsy Res 1999;37:81-7.  Back to cited text no. 137
    
138.
Brodie M, Richens A, Yuen A, Group ULCMT. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345:476-9.  Back to cited text no. 138
    
139.
Steiner T, Dellaportas C, Findley L, Gross M, Gibberd F, Perkin G, et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: A double-blind comparison with phenytoin. Epilepsia 1999;40:601-7.  Back to cited text no. 139
    
140.
Brodie MJ, Chadwick DW, Anhut H, Otte A, Messmer SL, Maton S, et al. Gabapentin versus lamotrigine monotherapy: A double-blind comparison in newly diagnosed epilepsy. Epilepsia 2002;43:993-1000.  Back to cited text no. 140
    
141.
Kwan P, Brodie MJ, Kälviäinen R, Yurkewicz L, Weaver J, Knapp LE. Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: A phase 3, double-blind, randomised, parallel-group trial. Lancet Neurol 2011;10:881-90.  Back to cited text no. 141
    
142.
Privitera M, Brodie M, Mattson R, Chadwick D, Neto W, Wang S. Topiramate, carbamazepine and valproate monotherapy: Double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003;107:165-75.  Back to cited text no. 142
    
143.
Ramsay E, Faught E, Krumholz A, Naritoku D, Privitera M, Schwarzman L, et al. Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: A randomized double-blind clinical trial. Epilepsia 2010;51:1970-7.  Back to cited text no. 143
    
144.
Bill PA, Vigonius U, Pohlmann H, Guerreiro CAM, Kochen S, Saffer D, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997;27:195-204.  Back to cited text no. 144
    
145.
Guerreiro MM, Vigonius U, Pohlmann H, de Manreza MLG, Fejerman N, Antoniuk SA, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997;27:205-13.  Back to cited text no. 145
    
146.
Christe W, Krämer G, Vigonius U, Pohlmann H, Steinhoff BJ, Brodie MJ, et al. A double-blind controlled clinical trial: Oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997;26:451-60.  Back to cited text no. 146
    
147.
Dam M, Ekberg R, Løyning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989;3:70-6.  Back to cited text no. 147
    
148.
Baulac M, Brodie MJ, Patten A, Segieth J, Giorgi L. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: A phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol 2012;11:579-88.  Back to cited text no. 148
    
149.
Brodie M, Perucca E, Ryvlin P, Ben-Menachem E, Meencke H-J, Group LMS. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007;68:402-8.  Back to cited text no. 149
    
150.
Trinka E, Marson AG, Van Paesschen W, Kälviäinen R, Marovac J, Duncan B, et al. KOMET: An unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. J Neurol Neurosurg Psychiatry 2013;84:1138-47.  Back to cited text no. 150
    
151.
Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 1998;32:554-63.  Back to cited text no. 151
    
152.
Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2003;2:404-9.  Back to cited text no. 152
    
153.
Levy RH. Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 1995;36:S8-S13.  Back to cited text no. 153
    


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4]
 
 
    Tables

  [Table 1], [Table 2], [Table 3]



 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow